Roche’s MabThera Recommended by NICE When TNF Inhibitors Fail

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended Roche’s MabThera plus methotrexate for rheumatoid arthritis when treatment with at least one tumor necrosis factor (TNF) inhibitor has failed. MabThera (rituximab) is a disease-modifying anti-rheumatic drug and cancer treatment, and methotrexate is indicated as a stand-alone treatment for severe psoriasis, according to draft recommendations NICE posted online.
International Pharmaceutical Regulatory Monitor